| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7fd38ff393036b78f4fa402ddeeae2d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate |
2018-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cd69f39546a0dd56e2cdcecb3252b98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dcbf39a244cfd72ead2ca533e2c566f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12166b19837b2fbd12e23ed6be55a11c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_350766a5a28304434d38f0ccafcc5cbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1b739304e7268731c717c7de578bd73 |
| publicationDate |
2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018207193-A1 |
| titleOfInvention |
Radiolabeled compounds that target organic cation transporters and uses thereof in radioimaging |
| abstract |
Radiolabeled quaternary ammonium salt compounds featuring a quinoline skeleton and uses thereof in radioimaging are provided. The radiolabeled compounds are usable for determining a presence and/or level and/or distribution of an organic cation transporter in a body of a patient and for determining if the patient has a disease or disorder that is treatable by or responsive to a therapy whose efficacy correlates with a presence and/or level of an organic cation transporter. Also provided is a use of these radiolabeled compounds in treating such a disease or disorder. The radiolabeled compounds are also usable for radioimaging OCT- expressing cells, tissues and/or organ, for determining a presence and/or level of an impaired structure or function of the OCT-expressing cells, tissues and/or organ and/or of a disease or disorder associated with such impaired structure and/or function. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020050729-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111349027-A |
| priorityDate |
2017-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |